EUCTR2016-003536-21-ES进行中（未招募）1 期
Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC - CheckMate 816: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 816
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 326
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Early stage (IB - IIIA), operable non-small cell lung cancer, confirmed in tissue.
- •Lung function capacity capable of tolerating the proposed lung surgery
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- •Available tissue of primary lung tumor.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 126
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •Presence of locally advanced, inoperable or metastatic disease.
- •Participants with active, known or suspected autoimmune disease.
- •Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors).
研究者
相似试验
招募中
1 期
A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)Early Stage Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2022-501360-18-00Bristol-Myers Squibb International Corporation386
进行中（未招募）
1 期
A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)EUCTR2016-003536-21-HUBristol-Myers Squibb International Corporation642
进行中（未招募）
1 期
A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)EUCTR2016-003536-21-GRBristol-Myers Squibb International Corporation350
进行中（未招募）
1 期
A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)Early Stage Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003536-21-ROBristol-Myers Squibb International Corporation642
已完成
3 期
A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma.GlioblastomaNL-OMON47552Bristol-Myers Squibb24